3月16日,诺诚健华医药有限公司(以下简称“诺诚健华”)宣布,中国首款、全球第二款进入临床的VAV1分子胶降解剂ICP-538完成首例受试者给药。 ICP-538是诺诚健华自主研发的新型口服高效、高选择性靶向VAV1的特异性分子胶降解剂,VAV1是T细胞和B细胞受体下游的关键蛋白。ICP-538通过选择性介导CRBNE3泛素连接酶与VAV1蛋白形成三元复合物,剂量依赖性地诱导VAV1蛋白快速高效...
Source Link3月16日,诺诚健华医药有限公司(以下简称“诺诚健华”)宣布,中国首款、全球第二款进入临床的VAV1分子胶降解剂ICP-538完成首例受试者给药。 ICP-538是诺诚健华自主研发的新型口服高效、高选择性靶向VAV1的特异性分子胶降解剂,VAV1是T细胞和B细胞受体下游的关键蛋白。ICP-538通过选择性介导CRBNE3泛素连接酶与VAV1蛋白形成三元复合物,剂量依赖性地诱导VAV1蛋白快速高效...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.